Daily Stock Analysis, CTIC, CTi Biopharma Corp, priceseries

CTi Biopharma Corp. Daily Stock Analysis
Stock Information
Open
0.93
Close
0.92
High
0.94
Low
0.90
Previous Close
0.91
Daily Price Gain
0.01
YTD High
1.48
YTD High Date
Jan 8, 2019
YTD Low
0.74
YTD Low Date
Jan 2, 2019
YTD Price Change
-0.01
YTD Gain
-0.85%
52 Week High
5.36
52 Week High Date
Jun 26, 2018
52 Week Low
0.60
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-2.78
52 Week Gain
-75.08%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 20. 2017
2.60
Jan 23. 2018
3.24
21 Trading Days
24.66%
Link
LONG
Feb 9. 2018
3.21
Mar 8. 2018
3.84
18 Trading Days
19.52%
Link
LONG
May 16. 2018
4.14
May 29. 2018
4.62
8 Trading Days
11.69%
Link
Company Information
Stock Symbol
CTIC
Exchange
NasdaqCM
Company URL
http://http://www.ctibiopharma.com
Company Phone
2062827100
CEO
James A. Bianco
Headquarters
Washington
Business Address
3101 WESTERN AVENUE, SUITE 600, SEATTLE, WA 98121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000891293
About

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.

Description

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.